Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Critical Care

Volumn 16, Issue 5, 2012, Pages

  Desmettre, Thibaut ^a   Dehours, Emilie ^b   Samama, Charles Marc ^c   Jhundoo, Suchin ^d   Pujeau, Frédéric ^e   Guillaudin, Christian ^f   Hecquart, Claudine ^g   Clerson, Pierre ^h   Crave, Jean C ⁱ   Jaussaud, Roland ^j  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b CHU PURPAN   (France)

^c HÔTEL DIEU   (France)

^d Urgences   (France)

^e CH Pau   (France)

^f Pharmacie   (France)

^g CHU CÔTE DE NACRE   (France)

^h Orgamétrie biostatistiques ^*  (France)

ⁱ Octapharma   (France)

^j SERVICE DE DERMATOLOGIE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; VITAMIN K GROUP; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES;

ABDOMINAL BLEEDING; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HEMATOMA; HEMATOTHORAX; HEMATURIA; HEMIPERICARDIUM; HEMOPERITONEUM; HEMOPTYSIS; HOSPITAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FRANCE; HEMORRHAGE; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; FEMALE; FRANCE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN K;

EID: 84866948177     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11669     Document Type: Article

References (50)

1. Pernod G, Godiér A, Gozalo C, Tremey B, Sié P. French National Authority for Health. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010, 126:e167-174. 10.1016/j.thromres.2010.06.017, 20630568.
2. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995, 333:11-17. 10.1056/NEJM199507063330103, 7776988.
3. Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006, 166:853-859. 10.1001/archinte.166.8.853, 16636210.
4. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002, 325:828-831. 10.1136/bmj.325.7368.828, 1124331, 12376447.
5. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348:423-428. 10.1016/S0140-6736(96)01109-9, 8709780.
6. Van der Meer FJ, Rosendaal FR. No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50 mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery. Ned Tijdschr Geneeskd 1993, 137:2223-2225.
7. Freeman WD, Aguilar MI. Management of warfarin-related intracerebral hemorrhage. Expert Rev Neurother 2008, 8:271-290. 10.1586/14737175.8.2.271, 18271712.
8. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007, 68:116-121. 10.1212/01.wnl.0000250340.05202.8b, 17210891.
9. Hanley JP. Warfarin reversal. J Clin Pathol 2004, 57:1132-1139. 10.1136/jcp.2003.008904, 1770479, 15509671.
10. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588-1593. 10.1161/01.STR.0000170642.39876.f2, 15947271.
11. Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care 2010, 12:403-413. 10.1007/s12028-009-9310-0, 19967567.
12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994, 120:897-902.
13. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
14. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, . American College of Chest Physicians Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 suppl):160S-198S. 10.1378/chest.08-0670, 18574265, American College of Chest Physicians.
15. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
16. Fredriksson K, Norrving B, Strömblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992, 23:972-977. 10.1161/01.STR.23.7.972, 1615547.
17. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004, 63:1059-1064. 10.1212/01.WNL.0000138428.40673.83, 15452298.
18. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164:880-884. 10.1001/archinte.164.8.880, 15111374.
19. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006, 37:256-262.
20. Seelig JM, Becker DP, Miller JD, Greenberg RP, Ward JD, Choi SC. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med 1981, 304:1511-1518. 10.1056/NEJM198106183042503, 7231489.
21. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993, 24:987-993. 10.1161/01.STR.24.7.987, 8322400.
22. Sjöblom L, Hårdemark HG, Lindgren A, Norrving B, Fahlén M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001, 32:2567-2574. 10.1161/hs1101.098523, 11692018.
23. Vigue B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care 2009, 13:209. 10.1186/cc7701, 2689453, 19486503.
24. Pindur G, Morsdorf S. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation. Thromb Res 1999, 95(4 Suppl 1):S57-61.
25. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105:91-99. 10.1016/S0002-9343(98)00198-3, 9727814.
26. Aiyagari V, Testai FD. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care 2009, 15:87-92. 10.1097/MCC.0b013e3283269e4d, 19300085.
27. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752.
28. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696. 10.1161/CIRCULATIONAHA.106.653048, 17515465.
29. Masotti L, Di Napoli M, Godoy DA, Rafanelli D, Liumbruno G, Koumpouros N, Landini G, Pampana A, Cappelli R, Poli D, Prisco D. The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke 2011, 6:228-240. 10.1111/j.1747-4949.2011.00595.x, 21557810.
30. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006, 37:151-155.
31. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
32. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, García RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007, 82:82-92.
33. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006, 4:1853-1863. 10.1111/j.1538-7836.2006.01986.x, 16961594.
34. Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES, Greenberg SM, Huang JN, MacDonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ, . American Heart Association Stroke Council and Council on Cardiovascular Nursing Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41:2108-2129. 10.1161/STR.0b013e3181ec611b, 20651276, American Heart Association Stroke Council and Council on Cardiovascular Nursing.
35. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. Recommendations for the management of intracranial haemorrhage-part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294-316.
36. Desmettre T, Dubart AE, Capellier G, Fanara B, Puyraveau M, Kepka S, Coquart J, Sheppard F, Tazarourte K. Emergency reversal of anticoagulation: The real use of prothrombin complex concentrates: A prospective multicenter two year French study from 2006 to 2008. Thromb Res 2012, 130:e178-e183. 10.1016/j.thromres.2012.05.029, 22726885.
37. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005, 115:455-459. 10.1016/j.thromres.2004.09.002, 15792675.
38. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006, 118:313-320. 10.1016/j.thromres.2005.08.005, 16182346.
39. Khorsand N, Veeger NJ, Muller M, Overdiek JW, Huisman W, van Hest RM, Meijer K. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. Transfus Med 2011, 21:116-123. 10.1111/j.1365-3148.2010.01050.x, 21073580.
40. Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 2003, 82:121-123.
41. Vigué B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, Martin L, Benhamou D. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007, 33:721-725. 10.1007/s00134-007-0528-z, 17260127.
42. Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006, 5:197-201. 10.1385/NCC:5:3:197, 17290088.
43. Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990, 21:726-730. 10.1161/01.STR.21.5.726, 2339452.
44. Makris M, Van Veen JJ. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?. Blood Transfus 2011, 9:117-119. 3096854, 21251466.
45. Imberti D, Barillari G, Biasioli C, Bianchi M, Contino L, Duce R, D'Incà M, Gnani MC, Mari E, Ageno W. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011, 9:148-155. 3096857, 21251465.
46. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T, . Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006, 66:1175-1181. 10.1212/01.wnl.0000208408.98482.99, 16636233, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators.
47. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, Skolnick BE, Davis SM, . Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 2007, 38:1072-1075. 10.1161/01.STR.0000258078.35316.30, 17290026, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators.
48. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999, 95(4 Suppl 1):S13-S17.
49. Köhler M, Heiden M, Harbauer G, Miyashita C, Mörsdorf S, Braun B, Ernert P, Wenzel E, Rose S, Pindur G. Comparison of different prothrombin complex concentrates--in vitro and in vivo studies. Thromb Res 1990, 60:63-70. 10.1016/0049-3848(90)90340-I, 2148989.
50. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008, 83:137-143. 10.1002/ajh.21046, 17729241.